BELPHARMED
ActiveSummary
The computed 12-month bankruptcy probability of BELPHARMED is 2.4% (moderate). The 2025 annual accounts show equity of €15,741 and a net result of €876. Equity is growing by about 5.2% per year across the filed financial years. Its solvency ranks better than 9% of 6,105 sector peers (NACE 46, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
28-09
NBB filing
Annual accounts filed
financial year 2025 · full format · 59 days late
2025
29-09
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format · 60 days late
2024
31-12
Financial
Weakest financial yearnet €468 ▼98.2%
Net result drops to €468, the lowest in the series; recovery starts the following year.
03-06
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
31-12
Financial
Highest result from 2021 to 2025net €25,626 ▲20.7%
Net result €25,626, the highest in the series.
31-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 31 days late
2022
14-10
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 75 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.